The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest

Haematologica

Volumn 98, Issue 11, 2013, Pages 1711-1717

  Ben Abdelali, Raouf ^a   Asnafi, Vahid ^a   Petit, Arnaud ^b   Micol, Jean Baptiste ^c   Callens, Céline ^a   Villarese, Patrick ^a   Delabesse, Eric ^d   Reman, Oumedaly ^e   Lepretre, Stephane ^f   Cahn, Jean Yves ^g   Guillerm, Gaelle ^h   Berthon, Céline ^h   Gardin, Claude ⁱ   Corront, Bernadette ^j   Leguay, Thibaut ^k   Béné, Marie Christine ^l   Ifrah, Norbert ^m   Leverger, Guy ^b   Dombret, Hervé ^c   Macintyre, Elizabeth ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b ARMAND TROUSSEAU HOSPITAL   (France)

^c UNIVERSITÉ PARIS DIDEROT   (France)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e CAEN UNIVERSITY HOSPITAL   (France)

^f ROUEN UNIVERSITY HOSPITAL   (France)

^g LABORATOIRE TIMC IMAG   (France)

^h CENTRE HOSPITALIER   (France)

ⁱ AVICENNE HOSPITAL   (France)

^j Centre Hospitalier de la Region d'Annecy   (France)

^k HAUT LÉVÊQUE HOSPITAL   (France)

^l NONE   (France)

^m ANGERS UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; T LYMPHOCYTE RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CALM AF10 GENE; CANCER PROGNOSIS; CANCER STAGING; CHILD; EVENT FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENOTYPE; HUMAN; INFANT; KARYOTYPING; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MATURATION ARREST; OVERALL SURVIVAL; PRE T LYMPHOCYTE; PRESCHOOL CHILD; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; T CELL LEUKEMIA;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; MONOMERIC CLATHRIN ASSEMBLY PROTEINS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 84887003185     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.086082     Document Type: Article

References (39)

1. Huguet F, Leguay T, Raffoux E, Thomas X, Beldjord K, Delabesse E, et al. Pediatricinspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009; 27(6): 911-8.
2. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004; 350(15): 1535-48.
3. Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007; 109(3): 944-50.
4. Harned TM, Gaynon P. Relapsed acute lymphoblastic leukemia: current status and future opportunities. Curr Oncol Rep. 2008; 10(6): 453-8.
5. Gameiro P, Mortuza FY, Hoffbrand AV, Foroni L. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements. Haematologica. 2002; 87(11): 1126-34.
6. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008; 111(4): 1827-33.
7. Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood. 2009; 114(25): 5136-45.
8. Ben Abdelali R, Asnafi V, Leguay T, Boissel N, Buzyn A, Chevallier P, et al. Pediatricinspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL study. Blood. 2011; 118(19): 5099-107.
9. Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, et al. Early Tcell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009; 10(2): 147-56.
10. Clappier E, Collette S, Grardel N, Girard S, Suarez L, Brunie G, et al. NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951. Leukemia. 2010; 24(12): 2023-31.
11. Kox C, Zimmermann M, Stanulla M, Leible S, Schrappe M, Ludwig WD, et al. The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia. 2010; 24(12): 2005-13.
12. Zuurbier L, Homminga I, Calvert V, te Winkel ML, Buijs-Gladdines JG, Kooi C, et al. NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Leukemia. 2010; 24(12): 2014-22.
13. Inukai T, Kiyokawa N, Campana D, Coustan-Smith E, Kikuchi A, Kobayashi M, et al. Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children's Cancer Study Group Study L99-15. Br J Haematol. 2012; 156(3): 358-65.
14. Van Vlierberghe P, Ambesi-Impiombato A, Perez-Garcia A, Haydu JE, Rigo I, Hadler M, et al. ETV6 mutations in early immature human T cell leukemias. J Exp Med. 2011; 208(13): 2571-9.
15. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012; 481 (7380): 157-63.
16. Bohlander SK, Muschinsky V, Schrader K, Siebert R, Schlegelberger B, Harder L, et al. Molecular analysis of the CALM/AF10 fusion: identical rearrangements in acute myeloid leukemia, acute lymphoblastic leukemia and malignant lymphoma patients. Leukemia. 2000; 14(1): 93-9.
17. Carlson KM, Vignon C, Bohlander S, Martinez-Climent JA, Le Beau MM, Rowley JD. Identification and molecular characterization of CALM/AF10 fusion products in T cell acute lymphoblastic leukemia and acute myeloid leukemia. Leukemia. 2000; 14(1): 100-4.
18. Tebar F, Bohlander SK, Sorkin A. Clathrin assembly lymphoid myeloid leukemia (CALM) protein: localization in endocyticcoated pits, interactions with clathrin, and the impact of overexpression on clathrinmediated traffic. Mol Biol Cell. 1999; 10(8): 2687-702.
19. Klebig ML, Wall MD, Potter MD, Rowe EL, Carpenter DA, Rinchik EM. Mutations in the clathrin-assembly gene Picalm are responsible for the hematopoietic and iron metabolism abnormalities in fit1 mice. Proc Natl Acad Sci USA. 2003; 100(14): 8360-5.
20. Greif PA, Tizazu B, Krause A, Kremmer E, Bohlander SK. The leukemogenic CALM/AF10 fusion protein alters the subcellular localization of the lymphoid regulator Ikaros. Oncogene. 2008; 27(20): 2886-96.
21. Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield VM, et al. hDOT1L links histone methylation to leukemogenesis. Cell. 2005; 121(2): 167-78.
22. Dik WA, Brahim W, Braun C, Asnafi V, Dastugue N, Bernard OA, et al. CALMAF10+ T-ALL expression profiles are characterized by overexpression of HOXA and BMI1 oncogenes. Leukemia. 2005; 19(11): 1948-57.
23. Okada Y, Jiang Q, Lemieux M, Jeannotte L, Su L, Zhang Y. Leukaemic transformation by CALM-AF10 involves upregulation of Hoxa5 by hDOT1L. Nat Cell Biol. 2006; 8(9): 1017-24.
24. Asnafi V, Radford-Weiss I, Dastugue N, Bayle C, Leboeuf D, Charrin C, et al. CALMAF10 is a common fusion transcript in T-ALL and is specific to the TCRgammadelta lineage. Blood. 2003; 102(3): 1000-6.
25. Dreyling MH, Schrader K, Fonatsch C, Schlegelberger B, Haase D, Schoch C, et al. MLL and CALM are fused to AF10 in morphologically distinct subsets of acute leukemia with translocation t(10; 11): both rearrangements are associated with a poor prognosis. Blood. 1998; 91(12): 4662-7.
26. Kumon K, Kobayashi H, Maseki N, Sakashita A, Sakurai M, Tanizawa A, et al. Mixed-lineage leukemia with t(10; 11)(p13; q21): an analysis of AF10-CALM and CALM-AF10 fusion mRNAs and clinical features. Genes Chromosomes Cancer. 1999; 25(1): 33-9.
27. Narita M, Shimizu K, Hayashi Y, Taki T, Taniwaki M, Hosoda F, et al. Consistent detection of CALM-AF10 chimaeric transcripts in haematological malignancies with t(10; 11)(p13; q14) and identification of novel transcripts. Br J Haematol. 1999; 105(4): 928-37.
28. Savage NM, Kota V, Manaloor EJ, Kulharya AS, Pierini V, Mecucci C, et al. Acute leukemia with PICALM-MLLT10 fusion gene: diagnostic and treatment struggle. Cancer Genet Cytogenet. 2010; 202(2): 129-32.
29. van Grotel M, Meijerink JP, Beverloo HB, Langerak AW, Buys-Gladdines JG, Schneider P, et al. The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocols. Haematologica. 2006; 91(9): 1212-21.
30. Asnafi V, Buzyn A, Thomas X, Huguet F, Vey N, Boiron JM, et al. Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study. Blood. 2005; 105(8): 3072-8.
31. Ballerini P, Landman-Parker J, Cayuela JM, Asnafi V, Labopin M, Gandemer V, et al. Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome. Haematologica. 2008; 93(11): 1658-65.
32. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 2008.
33. Shaffer LG, Slovak ML, Campbell LJ. ISCN (2009): International System of Human Cytogenetic Nomenclature, 2009.
34. Hochstenbach F, Brenner MB. T-cell receptor delta-chain can substitute for alpha to form a beta delta heterodimer. Nature. 1989; 340 (6234): 562-5.
35. Grossmann V, Bacher U, Kohlmann A, Artusi V, Klein HU, Dugas M, et al. EZH2 mutations and their association with PICALM-MLLT10 positive acute leukaemia. Br J Haematol. 2012; 157(3): 387-90.
36. Dadi S, Le Noir S, Payet-Bornet D, Lhermitte L, Zacarias-Cabeza J, Bergeron J, et al. TLX Homeodomain oncogenes mediate T Cell maturation arrest in T-ALL via interaction with ETS1 and suppression of TCRalpha gene expression. Cancer Cell. 2012; 21(4): 563-76.
37. Asnafi V, Beldjord K, Libura M, Villarese P, Millien C, Ballerini P, et al. Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy. Blood. 2004; 104(13): 4173-80.
38. Neumann M, Heesch S, Gokbuget N, Schwartz S, Schlee C, Benlasfer O, et al. Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations. Blood Cancer J. 2012; 2(1): e55.
39. Ntziachristos P, Tsirigos A, Vlierberghe PV, Nedjic J, Trimarchi T, Flaherty MS, et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med. 2012; 18(2): 298-303.